ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025
Depletion of marrow adipo-CAR cells in mice enhances bone formation by activating bone morphogenetic protein receptor (BMPR) in pre-osteoblasts.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Inhibition of Dot1L Histone Methyltransferase Expands Bone Injury-Responsive CXCL12bioRxiv : the preprint server for biology · 2026Article
- Multifunctional LepR⁺ skeletal stem/progenitor cells for bone and marrow homeostasis.Journal of bone and mineral metabolism · 2026Review
- Bone marrow adipoq-lineage cells in regulating the bone and marrow microenvironment: identities, functions, and mechanisms.Frontiers in endocrinology · 2026Review
- Bone marrow adipocytes: key players in vascular niches, aging, and disease.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diphtheria toxin (DT)-mediated deletion of marrow cells expressing its receptor (DTR), exclusively in adiponectin (Adipoq)-positive cells, results in profound osteosclerosis, a process driven by activation of bone morphogenetic protein receptor (BMPR) signaling. This enhancement of bone mass is associated with removal of Grem1 and Chrdl1, but the cellular source of these BMPR inhibitors, and whether they mediate this unique skeletal event, has not been established. In this study, we found that replacing the depleted BMPR inhibitors, using nanoparticles bearing their mRNAs, attenuates the osteogenic effect of Adipoq-positive cell depletion, confirming the essential role of Grem1 and Chrdl1 in the osteosclerotic process. Depletion of these BMPR inhibitors is accompanied by elimination of Cxcl12 and Lepr, suggesting that the Adipoq-positive subset of Cxcl12-abundant reticular (adipo-CAR) cells are the exclusive producers of Grem1 and Chrdl1 in marrow. While ablation of adipo-CAR cells does not increase osteo-CARs in the marrow, it activates BMPR in Col1*3.6-positive pre-osteoblasts, leading to their proliferation. Deletion of proliferating Col1*3.6-positive cells completely arrests bone formation induced by adipo-CAR cell ablation, suggesting that committed pre-osteoblasts, rather than earlier osteo-CARs, serve as the osteoprogenitors responsible for the new bone formation. The skeletal effects of eliminating marrow cells expressing leptin receptor (Lepr), also a marker of CAR cells, mirrors that induced by depleting those expressing adiponectin, including its initiation by BMPR activation in both male and female mice. Thus, marrow-residing Adipoq/Lepr-positive CAR cells limit excessive skeletal mass by producing BMPR inhibitors, while their depletion leads to significant osteosclerosis through BMPR activation and pre-osteoblast proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.